Drug Combination for Treatment of Proliferative Diseases

Angiogenesis inhibitory drug combination obtained according to a specific algorithm, preferably a FSC, in which an initial combination of drugs is iteratively adjusted. The drug combination according to the invention may advantageously comprise a RAPTA-C compound. In a more specific case the combination comprises RAPTA-C and eriotinib.


Year:
2017
Other identifiers:
EPO Family ID: 52875103
TTO: 6.1380
Laboratories:




 Record created 2017-05-02, last modified 2018-09-13


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)